Engineered Cytokine Signaling to Improve CAR T Cell Effector Function is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 156 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: 1F31CA250401-01A1
Development of Glypican-2 redirected T cells for the Treatment of Neuroblastoma
NCI NIH HHS
Grant: F31 CA250401
NINDS NIH HHS
Grant: R01 NS106379
National Institutes of Health
Grant: 5R01NS106379-03
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy
European Commission
Grant: 250401
European Union Contest for Young Scientists 2009
FWCI
7.47
Citation Percentile
1.0%
Influential Citations
2
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes
Additional file 1 of Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes
Additional file 1 of CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
Additional file 1 of CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma